WAC and ASP of Neulasta (pegfilgrastim) biosimilars in the U.S. 2022
As of July 2022, biosimilar Nyvepria (pegfilgrastim-apgf) launched at an average sales price of 16 percent higher than Neulasta's ASP, while the biosimilar drug Fulphila (pegfilgrastim-jmdb) launched at an average sales price of six percent less than Neulasta's. This statistic illustrates the wholesale acquisition cost and average sales price of Neulasta (pegfilgrastim) biosimilars in the United States.